US Markets

Vertex to buy cell therapy developer Semma for $950 mln

Credit: REUTERS/BRIAN SNYDER

Vertex Pharmaceuticals Inc said on Tuesday it would buy privately held Semma Therapeutics for $950 million in cash with an aim to develop potentially curative stem-cell based treatments for diabetes.

Adds details on Semma's therapy, background

Sept 3 (Reuters) - Vertex Pharmaceuticals Inc VRTX.O said on Tuesday it would buy privately held Semma Therapeutics for $950 million in cash with an aim to develop potentially curative stem-cell based treatments for diabetes.

The deal represents Vertex's foray into a new treatment space, as the company typically develops treatments for cystic fibrosis, an inherited disorder that causes damage to the lung and digestive system.

"We see a substantial opportunity to transform the treatment paradigm for type 1 diabetes, a specialty disease cared for by endocrinologists," said Vertex's Chief Executive Officer Jeffrey Leiden.

Semma focuses on developing cell-based therapies that have been shown to control blood glucose levels in preclinical studies, and also develops a medical device to protect these cells from being attacked by the body's immune system.

Vertex expects to close the acquisition in the fourth quarter this year.

Shares of Vertex were up 1.2% at $182.1 in light premarket trading.

(Reporting by Manas Mishra in Bengaluru; Editing by Arun Koyyur and Shinjini Ganguli)

((Manas.Mishra@thomsonreuters.com; within U.S. +1 646 223 8780, outside U.S. +91 806749 8325;))

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Latest Markets Videos

Reuters

Reuters, the news and media division of Thomson Reuters, is the world’s largest international multimedia news provider reaching more than one billion people every day. Reuters provides trusted business, financial, national, and international news to professionals via Thomson Reuters desktops, the world's media organizations, and directly to consumers at Reuters.com and via Reuters TV.

Learn More